Bendix G, Bjelle A, Holmberg E
Department of Rheumatology, University of Gothenburg, Sweden.
Scand J Rheumatol. 1995;24(2):79-84. doi: 10.3109/03009749509099289.
The cancer risk was studied by comparison of 305 rheumatoid arthritis (RA) patients exposed to Proresid during a mean time of 22 months and 305 RA patients exposed to sodium aurothiomalate during a mean time of 19 months with the regional cancer register. The mean observation time was 6.9 years (2,117 person-years) for the Proresid-treated and 7.5 years (2,293 person-years) for the gold-treated patients. No increased risk of total malignancies was observed for either group. However, looking at separate tumours, an increased risk of lymphoma and leukemia was found although only significant in the gold-treated group. It was not correlated to dosage or duration of either therapy. The increased risk is consistent with earlier reports of an increased risk of hematopoietic malignancies in RA patients. Marginal over and underreporting, particularly of hematopoietic malignancies, were observed, mainly due to clinicians' failure to report and to recall false reports.
通过将305名平均暴露于丙磺舒22个月的类风湿性关节炎（RA）患者和305名平均暴露于硫代苹果酸金钠19个月的RA患者与地区癌症登记处进行比较，研究了癌症风险。丙磺舒治疗组的平均观察时间为6.9年（2117人年），金制剂治疗组为7.5年（2293人年）。两组均未观察到总恶性肿瘤风险增加。然而，在单独分析肿瘤时，发现淋巴瘤和白血病风险增加，尽管仅在金制剂治疗组中具有统计学意义。它与任何一种治疗的剂量或持续时间均无关联。风险增加与先前关于RA患者造血系统恶性肿瘤风险增加的报道一致。观察到报告略有高估和低估，尤其是造血系统恶性肿瘤，主要是由于临床医生未报告以及错误报告的回忆。
